Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly and Co results of phase III hepatocellular carcinoma trial did not meet its primary endpoint


Wednesday, 11 Jun 2014 08:00am EDT 

Eli Lilly and Co:Says that the Phase III REACH trial of CYRAMZA (ramucirumab) in patients with hepatocellular carcinoma, also known as liver cancer, did not meet its primary endpoint.Says overall survival favored the CYRAMZA arm but was not statistically significant.Encouraging single agent CYRAMZA activity was observed, with meaningful improvements in key secondary endpoints of progression-free survival, overall response rate and time to progression. 

Company Quote

66.53
-0.06 -0.09%
19 Sep 2014